Thanks Rocky, just doing some DD! lets see how the

Thanks Rocky, just doing some DD! lets see how the CC goes tomorrow! the OTC Generics from the website look interesting! Go SCRC! Tut

here's a few that are for some serious diease's! from the ScripsAmerica website under OTC Generics, can you Imagine these in RapiMeds for the elderly in Nursey homes, Prisions, Hospitals.... Etc


Parcopa

Parcopa® (carbidopa and levodopa orally disintegrating tablets) is a combination of carbidopa and levodopa for the treatment of Parkinson’s diseasehttp://www.drugs.com/pro/parcopa.html# and syndrome. Parcopa® is an orally administered formulation of carbidopa and levodopa which rapidly disintegrates on the tongue and does not require water to aid dissolution or swallowing.



FazaClo

is an a typical antipsychotic used for the management of treatment-resistant schizophrenia.

FazaClo is also used for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are at chronic risk for re-experiencing suicidal behavior. People with schizoaffective disorder have symptoms of both schizophrenia and mood disorders, such as mental or physical mania (overactivity).

Zomig

Zolmitriptan is a selective serotonin receptor agonist of the 1B and 1D subtypes. It is a triptan, used in the acute treatment of migraine attacks with or without aura and cluster headaches.

Zolmitriptan is marketed by AstraZeneca with the brand names Zomig, Zomigon (Argentina, Canada & Greece), AscoTop (Germany) and Zomigoro (France). In 2008, Zomig generated nearly $154 million in sales.[1]

AstraZeneca's U.S. patent on Zomig tablets expired on November 14, 2012, and its pediatric exclusivity extension expired on May 14, 2013.[2] The patent in certain European countries has already expired too, and generic drug maker Actavis released a generic version in those countries, starting in March 2012.[3]